Business Context and Reporting Period
This Form 6-K summarizes GSK plc's financial results for the second quarter (Q2) and first half (H1) of 2022, issued on July 27, 2022. The reporting period marks GSK's first results as a newly focused biopharma company following the successful demerger and listing of its Consumer Healthcare business as Haleon on July 18, 2022. Consequently, Consumer Healthcare is now presented as a discontinued operation. All earnings per share (EPS) and dividend figures have been retrospectively adjusted to reflect a share consolidation (4 new shares for every 5 existing shares) completed on July 18, 2022.
Key Financial Metrics
| Metric | Q2 2022 | Q2 2021 | Growth (AER) | Growth (CER) |
|---|---|---|---|---|
| Turnover | £6.9 billion | £5.8 billion | +19% | +13% |
| Total Continuing Operating Profit | £1.1 billion | £1.3 billion | -15% | -35% |
| Adjusted Operating Profit | £2.0 billion | £1.6 billion | +22% | +7% |
| Adjusted Operating Margin | 29.0% | 28.1% | N/A | N/A |
| Total EPS (Continuing) | 17.5p | 30.3p | -42% | -58% |
| Adjusted EPS | 34.7p | 28.2p | +23% | +6% |
| Cash from Operations (Continuing) | £1.6 billion | £1.4 billion | +17% | N/A |
| Free Cash Flow (Continuing) | £0.3 billion | (£0.02 billion) | >100% | N/A |
Debt and Liquidity: Total net debt at June 30, 2022, was £21.5 billion, an increase of £1.6 billion from year-end 2021. This increase was primarily driven by dividends paid to shareholders (£2.1 billion) and adverse exchange impacts, partially offset by strong free cash flow generation. The balance sheet was strengthened by a dividend of over £7 billion received from Haleon.
Material Changes vs. Prior Period
- Revenue Growth: Total sales grew 19% at actual exchange rates (AER) and 13% at constant exchange rates (CER). Excluding COVID-19 solutions, sales grew 16% AER and 10% CER.
- Specialty Medicines: Sales of £2.7 billion (+44% AER, +35% CER), driven by HIV (+14% AER), Oncology (+29% AER), and Immuno-inflammation (+32% AER). COVID-19 solution (Xevudy) sales were £0.5 billion.
- Vaccines: Sales of £1.7 billion (+9% AER, +3% CER). Shingrix sales more than doubled to £731 million.
- General Medicines: Sales of £2.5 billion (+5% AER, +2% CER), with Trelegy growth offsetting generic competition.
- Profitability Divergence: While Adjusted Operating Profit grew 22% AER, Total Operating Profit declined 15% AER. This divergence was primarily due to increased contingent consideration charges (£699 million) driven by exchange rates and an adverse comparison to a £325 million tax credit in Q2 2021.
- COVID-19 Impact: Lower margin COVID-19 solutions (Xevudy) reduced Adjusted Operating Profit growth by approximately 16% AER and Adjusted EPS growth by 20% AER.
Guidance, Outlook, and Risks
2022 Guidance (CER, excluding COVID-19 solutions):
- Sales Growth: Raised to 6% to 8% (previously 5% to 7%).
- Adjusted Operating Profit Growth: Raised to 13% to 15% (previously 12% to 14%).
- Adjusted EPS Growth: Expected to grow around 1% lower than Adjusted Operating Profit.
Management Commentary: CEO Emma Walmsley highlighted strong commercial execution and a record quarter for Shingrix. The company expects lower reported growth in H2 2022 due to challenging H2 2021 comparators and increased R&D spend. Specialty Medicines sales are expected to grow ~10% CER for the full year, while General Medicines may show a slight decrease due to genericization.
Risks and Contingencies:
- Contingent Consideration: Significant volatility in earnings due to fair value re-measurement of liabilities related to ViiV Healthcare (Shionogi) and Novartis Vaccines, heavily influenced by exchange rates and sales forecasts.
- Legal Matters: Ongoing litigation and government investigations; aggregate provision for legal disputes was £0.2 billion.
- COVID-19 Dynamics: Continued uncertainty regarding variants and government demand for COVID-19 solutions.
- Supply Chain: Risks related to supply continuity and increased freight/distribution costs.
Unusual Items:
- Demerger: Haleon separation completed July 18, 2022. A gain on distribution is expected to be recognized in Q3 2022.
- Acquisitions: Completed acquisition of Sierra Oncology (July 1, 2022) and proposed acquisition of Affinivax (expected Q3 2022).
- Gilead Settlement: Received £0.9 billion upfront income in H1 2022 from a patent settlement.
Investor Verification Checklist
- Adjusted vs. Total Results: Verify the reconciliation between Total and Adjusted results, specifically the £699 million contingent consideration charge and the £325 million prior-year tax credit, which significantly distort Total EPS.
- COVID-19 Exposure: Assess the sustainability of growth excluding COVID-19 solutions (Xevudy), as H2 2022 sales for these solutions are expected to be substantially lower.
- Shingrix Sustainability: Confirm the durability of Shingrix growth, noting management's expectation of slightly lower H2 sales due to H1 channel stocking in the US.
- Dividend Policy: Review the declared Q2 dividend of 16.25p/share and the full-year expectation of 61.25p/share, ensuring understanding of the share consolidation impact.
- Net Debt Trajectory: Monitor the impact of the £7 billion Haleon dividend on GSK's net debt position and future leverage ratios.